Brokers Offer Predictions for SAGE Q1 Earnings

Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Sage Therapeutics in a research report issued on Wednesday, April 30th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will post earnings per share of ($0.82) for the quarter. HC Wainwright currently has a "Neutral" rating and a $12.00 target price on the stock. The consensus estimate for Sage Therapeutics' current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for Sage Therapeutics' Q2 2026 earnings at ($0.84) EPS, Q3 2026 earnings at ($0.68) EPS and Q4 2026 earnings at ($0.68) EPS.

Other research analysts have also issued research reports about the company. Wedbush restated a "neutral" rating and set a $6.00 price objective on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Scotiabank cut their target price on Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a research note on Wednesday, February 12th. StockNews.com upgraded shares of Sage Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday. Canaccord Genuity Group cut their price objective on shares of Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating on the stock in a research report on Wednesday, February 12th. Finally, Needham & Company LLC restated a "hold" rating on shares of Sage Therapeutics in a research report on Friday, April 25th. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $8.81.

Sage Therapeutics Stock Down 2.4 %

SAGE stock traded down $0.18 during midday trading on Thursday, reaching $7.30. The company had a trading volume of 1,060,063 shares, compared to its average volume of 1,221,130. The firm has a market capitalization of $457.13 million, a PE ratio of -1.11 and a beta of 0.20. The stock has a 50 day moving average price of $7.54 and a 200 day moving average price of $6.78. Sage Therapeutics has a fifty-two week low of $4.62 and a fifty-two week high of $14.31.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. The business had revenue of $14.06 million for the quarter, compared to the consensus estimate of $14.12 million. During the same quarter in the previous year, the firm earned ($1.80) EPS. The firm's revenue for the quarter was up 78.0% on a year-over-year basis.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. CWM LLC lifted its holdings in Sage Therapeutics by 1,943.1% in the 1st quarter. CWM LLC now owns 61,416 shares of the biopharmaceutical company's stock valued at $488,000 after acquiring an additional 58,410 shares during the last quarter. Cerity Partners LLC bought a new stake in shares of Sage Therapeutics in the 1st quarter worth approximately $398,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Sage Therapeutics during the first quarter valued at approximately $347,000. Pallas Capital Advisors LLC bought a new stake in Sage Therapeutics during the first quarter worth approximately $166,000. Finally, Merit Financial Group LLC acquired a new position in Sage Therapeutics in the first quarter worth approximately $87,000. Institutional investors own 99.22% of the company's stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.